NCT05050149 - Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

November 15, 2022

Study Completion Date

December 15, 2022

Conditions

Microcystic Lymphatic Malformation

Interventions

DRUG

PTX-022

Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations

Trial Locations (7)

Vascular Birthmark Institute, New York

Children's Hospital of Pennsylvania (CHOP), Philadelphia

Cincinnati Children's Hospital, Cincinnati

Minnesota Clinical Study Center, Fridley

Arkansas Children's Hospital, Little Rock

Stanford University, Palo Alto

Oregon Health and Science University, Portland